Michael T Mccabe

List of Publications by Year
in descending order

26 papers	4,896 citations	361413 20 h-index	552781 26 g-index
27 all docs	27 docs citations	27 times ranked	8265 citing authors

#	Article	IF	Citations
1	Structural characterization of dicyanopyridine containing DNMT1-selective, non-nucleoside inhibitors. Structure, 2022, 30, 793-802.e5.	3.3	11
2	Chromosome-specific retention of cancer-associated DNA hypermethylation following pharmacological inhibition of DNMT1. Communications Biology, 2022, 5, .	4.4	2
3	PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. Cancer Discovery, 2022, 12, 2120-2139.	9.4	14
4	<i>In vitro</i> and <i>in vivo</i> induction of fetal hemoglobin with a reversible and selective DNMT1 inhibitor. Haematologica, 2021, 106, 1979-1987.	3.5	41
5	Dnmt1 has de novo activity targeted to transposable elements. Nature Structural and Molecular Biology, 2021, 28, 594-603.	8.2	83
6	Fragment-based Scaffold Hopping: Identification of Potent, Selective, and Highly Soluble Bromo and Extra Terminal Domain (BET) Second Bromodomain (BD2) Inhibitors. Journal of Medicinal Chemistry, 2021, 64, 10772-10805.	6.4	17
7	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nature Cancer, 2021, 2, 1002-1017.	13.2	99
8	A Chemical Acetylation-Based Mass Spectrometry Platform for Histone Methylation Profiling. Molecular and Cellular Proteomics, 2021, 20, 100067.	3.8	3
9	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. Nature Cancer, 2021, 2, 1002-1017.	13.2	23
10	Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. Cancer Cell, 2019, 36, 100-114.e25.	16.8	196
11	An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer. Cancer Cell, 2019, 36, 385-401.e8.	16.8	359
12	Lysine specific demethylase 1 inactivation enhances differentiation and promotes cytotoxic response when combined with all-<i>trans</i> retinoic acid in acute myeloid leukemia across subtypes. Haematologica, 2019, 104, 1156-1167.	3.5	50
13	Signaling function of PRC2 is essential for TCR-driven T cell responses. Journal of Experimental Medicine, 2018, 215, 1101-1113.	8.5	40
14	MEK inhibitors overcome resistance to BET inhibition across a number of solid and hematologic cancers. Oncogenesis, 2018, 7, 35.	4.9	28
15	Activation of the p53-MDM4 regulatory axis defines the anti-tumour response to PRMT5 inhibition through its role in regulating cellular splicing. Scientific Reports, 2018, 8, 9711.	3.3	128
16	CARM1 Is Essential for Myeloid Leukemogenesis but Dispensable for Normal Hematopoiesis. Cancer Cell, 2018, 33, 1111-1127.e5.	16.8	48
17	Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. Science Translational Medicine, 2017, 9, .	12.4	165
18	Targeting Histone Methylation in Cancer. Cancer Journal (Sudbury, Mass), 2017, 23, 292-301.	2.0	54

#	Article	IF	Citations
19	Identification of a CARM1 Inhibitor with Potent In Vitro and In Vivo Activity in Preclinical Models of Multiple Myeloma. Scientific Reports, 2017, 7, 17993.	3.3	85
20	The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nature Communications, 2015, 6, 6051.	12.8	281
21	EZH2 as a potential target in cancer therapy. Epigenomics, 2014, 6, 341-351.	2.1	84
22	A687V EZH2 Is a Driver of Histone H3 Lysine 27 (H3K27) Hypertrimethylation. Molecular Cancer Therapeutics, 2014, 13, 3062-3073.	4.1	44
23	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. Cancer Cell, 2013, 23, 677-692.	16.8	706
24	Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2989-2994.	7.1	445
25	Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Medicinal Chemistry Letters, 2012, 3, 1091-1096.	2.8	332
26	EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature, 2012, 492, 108-112.	27.8	1,558